
51 - 200 employees
Founded 1999
🧬 Biotechnology
💊 Pharmaceuticals
🏥 Healthcare
Biotechnology • Pharmaceuticals • Healthcare
Candel Therapeutics is a clinical-stage biotechnology company developing off-the-shelf engineered viral immunotherapies for solid tumors. The company advances two genetically modified viral platforms: aglatimagene besadenovec (CAN-2409), an intratumoral adenoviral gene therapy encoding HSV-thymidine kinase used with oral prodrugs to induce immunogenic cell death and CD8+ T cell–mediated anti-tumor immunity; and linoserpaturev (CAN-3110), a replication-competent, Nestin-promoter–controlled oncolytic HSV designed for tumor-specific killing (notably high-grade glioma). Candel reports Phase 3 data for aglatimagene in prostate cancer with strong pathological response rates and has received FDA Fast Track and RMAT designations; it positions itself as an immuno-oncology company focused on improving outcomes and preserving quality of life.
🔥 0 minutes ago
Biomarker operations manager overseeing biospecimen logistics and vendor execution. Supporting Candel’s clinical-stage cancer immunotherapy programs through compliant, inspection-ready trial operations.